SAB Biotherapeutics (SABS) Expected to Release Quarterly Earnings on Thursday

Key Points

• SAB Biotherapeutics is expected to report Q3 2026 results before the market opens on Thursday, November 5. Analysts forecast a loss of $0.27 per share and revenue of approximately $0.12 million; the earnings call is scheduled for 8:30 a.m. ET.
• The company previously reported a quarterly loss of $0.28 per share, matching consensus estimates. Analysts project full-year EPS of negative $1.17 and next-year EPS of negative $0.79.
• SABS recently traded at $3.35, with a market capitalization of about $304.8 million and a 12-month range of $2.44 to $5.15. Despite an overall “Moderate Buy” consensus and a $12 target price, some rating services maintain sell recommendations.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $0.12 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28). On average, analysts expect SAB Biotherapeutics to post ($1.17) EPS for the current fiscal year and ($0.79) EPS for the next fiscal year.

SAB Biotherapeutics Price Performance

SABS stock opened at $3.35 on Friday. The firm has a 50 day moving average of $3.26 and a 200-day moving average of $3.68. SAB Biotherapeutics has a 12-month low of $2.44 and a 12-month high of $5.15. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The company has a market cap of $304.82 million, a price-to-earnings ratio of -2.58 and a beta of 0.58.

Wall Street Analyst Weigh In

SABS has been the subject of several research analyst reports. Wall Street Zen raised SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 10th. Weiss Ratings raised SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 17th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals' plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.